AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30841568
Drug: Non-steroid anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid anti-inflammatory drugs (NSAIDs) use
Trial: 27322597
Drug: Guarana 50
RxNorm normalized name: GUARANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guarana 50 mg twice a day during chemoradiotherapy
Trial: 21716983
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine digluconate solution used twice daily for 3 months
Trial: 19699918
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion at 4 cc/hour for 100 hours
Trial: 19699918
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline solution) infusion
Trial: 12724679
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion
Trial: 3898670
Drug: Dipyridamole (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (8 mg for adults, 50 mg for schoolchildren, 24 mg for kindergarten children) administered orally every 8 days during the epidemic period (January-March 1983)
Trial: 29743334
Drug: High water
RxNorm normalized name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High water (HW) intake based on an individualised water intake prescription
Trial: 26467700
Drug: Relamorelin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relamorelin, 100 μg, SQ
Trial: 25812762
Drug: Best endovascular
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best endovascular therapy
Trial: 25812762
Drug: Best open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best open surgical treatment
Trial: 21474566
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (upper canines)
Trial: 21474566
Drug: Miniscrew group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miniscrew group (miniscrew implants)
Trial: 11083486
Drug: Rutin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutin supplementation (500 mg)
Trial: 8633816
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (zidovudine with didanosine or zalcitabine)
Trial: 8633816
Drug: Sequential monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential monotherapy (with didanosine or zalcitabine)
Trial: 1997702
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment (150 micrograms ethinyl estradiol daily and 80 mg polyestradiol monthly)
Trial: 31809265
Drug: Additional oral
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional oral medications (0, 1, or 2+ medications)
Trial: 31809265
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) in girls
Trial: 15656907
Drug: Conservative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative care protocol (visits with a hand therapist, exercises, self-care booklet, work modification/activity restriction, B6 therapy, ultrasound, possible steroid injections)
Trial: 1782100
Drug: Control day
RxNorm normalized name: Avobenzone 30 mg in 1 mL / Octinoxate 75 mg in 1 mL TOPICAL LOTION [Oil-Control Day SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control day (no treatment)
Trial: 30626939
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of Notch signaling using neutralizing antibody or pharmaceutical inhibitor
Trial: 28353593
Drug: Warming infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming infusion (fluid warmed to 35°C)
Trial: 28353593
Drug: Control (room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (room temperature infusion at 22-23°C)
Trial: 26514332
Drug: Buccal spray
RxNorm normalized name: Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal spray (500 IU, delivering 1000 IU in two spray shots)
Trial: 26514332
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule (1000 IU)
Trial: 11344204
Drug: Morning hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning hypoglycemia (2.9 +/‐ 0.1 mmol/L)
Trial: 11344204
Drug: Euglycemic control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemic control (5.1 +/‐ 0.1 mmol/L)
Trial: 10437184
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no change in prescribed medication)
Trial: 2580866
Drug: Acebutolol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (600 mg tid)
Trial: 2580866
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg tid)
Trial: 31020598
Drug: Dosing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of low-molecular-weight heparins (LMWHs)
Trial: 24891327
Drug: LVR coil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVR coil treatment
Trial: 20650046
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 0.2 microg/kg/min (G1)
Trial: 20650046
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 0.2 microg/kg/min and low doses of ketamine infusion 1 microg/kg/min (G2)
Trial: 8772222
Drug: Synthetic natural
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic natural pentasaccharide (NP) administered subcutaneously at doses from 1.43 to 22.9 mg (1000 to 16,000 anti‐Xa IU)
Trial: 8772222
Drug: Synthetic natural
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic natural pentasaccharide (NP) administered at various dosages once or twice a day for 7 days
Trial: 8772222
Drug: Synthetic natural
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic natural pentasaccharide (NP) at highest dose regimens (single injection of 26.6 mg and repeated injections of 11.4 mg)
Trial: 2292115
Drug: TCM prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM prescriptions of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy
Trial: 2292115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chinese medicine with chemotherapy
Trial: 26401735
Drug: Intravenous sugammadex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sugammadex (2 mg kg⁻¹)
Trial: 26401735
Drug: No reversal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No reversal agents (Control Group II)
Trial: 24098467
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg/day) in DM subgroup (n = 63)
Trial: 24098467
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day) in DM subgroup (n = 62)
Trial: 21320950
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy (melphalan with or without topotecan)
Trial: 19158122
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral theophylline (100 mg twice daily)
Trial: 19158122
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (including systemic steroids)
Trial: 8061738
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody treatment for endotoxin-induced septic shock
Trial: 8061738
Drug: New techniques
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New techniques to supplement basic cardiopulmonary resuscitation
Trial: 8061738
Drug: Ribavirin treatment
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin treatment for respiratory syncytial virus infection in mechanically ventilated infants
Trial: 2969169
Drug: 2 l
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l O2/min
Trial: 2969169
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l O2/min
Trial: 31729999
Drug: Immediate antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antiretroviral therapy (ART) starting within 7 days after initiation of opportunistic infection (OI) treatment
Trial: 31729999
Drug: Deferred antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred antiretroviral therapy (ART) starting after completing OI-therapy
Trial: 22204723
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg daily) plus elastic stockings with graduated compression
Trial: 18196200
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment during TMS
Trial: 10711861
Drug: Oral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-arginine (9 g daily for 1 month)
Trial: 26300945
Drug: Sanfu herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanfu herbal patch (SHP)
Trial: 21226939
Drug: Titrated therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated therapeutic hypothermia (32-35 °C) with intravenous 0.9% saline (20-30 ml/kg) and maintained for at least 48 hours or longer as needed to keep intracranial pressure <20 mmHg.
Trial: 18653816
Drug: Medication Discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Discharge Plan (MDP)
Trial: 11410720
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day)
Trial: 9248764
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) 60 mg.kg-1 on day 1 plus calcitriol 1 microgram per day orally for 5 consecutive days
Trial: 9248764
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) 60 mg.kg-1 on day 1
Trial: 8363113
Drug: N‐acetylcysteine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐acetylcysteine (140 mg/kg)
Trial: 8363113
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (60 g) + N‐acetylcysteine (235 mg/kg)
Trial: 3306781
Drug: Iopamidol (nonionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (nonionic agent)
Trial: 3306781
Drug: Iothalamate meglumine
RxNorm normalized name: Iothalamate Meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iothalamate meglumine (ionic agent)
Trial: 30107239
Drug: Standard home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard home oxygen therapy management
Trial: 26429200
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day with ubiquinol supplementation
Trial: 25265769
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine 10 mg plus fentanyl 10 g
Trial: 25265769
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 11 mg plus fentanyl 10 g
Trial: 25265769
Drug: Intrathecal levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal levobupivacaine 11 mg plus fentanyl 10 g
Trial: 22430286
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stent
Trial: 18779612
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/d orally)
Trial: 18779612
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2 infusion on days 1 and 8 of a 21-day cycle)
Trial: 15929952
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg q.d. for 2 weeks)
Trial: 3131470
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin acetate (0.4 microgram/kg)
Trial: 3131470
Drug: Intranasal drops
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal drops and intranasal spray of desmopressin acetate
Trial: 3131470
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin acetate
Trial: 3131470
Drug: Euglobulin lysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglobulin lysis time, t-PA activity, t-PA antigen levels, and t-PA fast-acting inhibitor (PAI) level
Trial: 30672235
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of superficial needling technique and mild moxibustion
Trial: 15042531
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in combination with fludarabine and cyclophosphamide
Trial: 15042531
Drug: Increased dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dosing intensity and frequency of rituximab
Trial: 11377899
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (controls, Group 4)
Trial: 9442547
Drug: Sulpiride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (200 mg daily for 30 days)
Trial: 7955519
Drug: HIV-1LAI recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, 50-micrograms doses
Trial: 7955519
Drug: HIV-1LAI recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 1 (0, 1, 2, and 5 months)
Trial: 7955519
Drug: HIV-1LAI recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 2 (0, 1, 2, 3, and 4 months)
Trial: 31736069
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg/mL intravenously)
Trial: 31736069
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 μg rectally)
Trial: 28320406
Drug: Three-session manualised
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-session manualised psychosocial group intervention and BBV transmission information booklet plus treatment as usual (TAU)
Trial: 29208190
Drug: Information booklet
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information booklet plus treatment as usual (TAU)
Trial: 25569072
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide and sodium hypochlorite solution (control)
Trial: 22022214
Drug: Aflapin(®) 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflapin(®) 100 mg daily for 30 days
Trial: 15988404
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs (methimazole 5-20 mg/die/os) and diphosphonates (alendronate 10 mg/die/os)
Trial: 15988404
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs only
Trial: 12629097
Drug: rhIGF‐I (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (30 micro g/kg sc twice daily)
Trial: 7698300
Drug: Control cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycles (CHOP chemotherapy)
Trial: 2642668
Drug: Morphine-proglumide mixtures
RxNorm normalized name: proglumide
DrugBank: Proglumide (DB13431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-proglumide mixtures (proglumide doses per demand: 0, 50 micrograms, 100 micrograms, or 50 mg)
Trial: 2642668
Drug: Morphine (demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (demand dose 3 mg; infusion rate 0.36 mg/hr; lockout time 2 minutes; hourly maximum dose 15 mg/hr)
Trial: 31924543
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks, IAI 2 mg every 8 weeks after 5 monthly doses
Trial: 29888580
Drug: Methotrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10 mg, once a week) and Celecoxib (0.2 g, once a day)
Trial: 18840204
Drug: 24% oral
RxNorm normalized name: Entero VU, 24% oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% oral sucrose solution
Trial: 16861101
Drug: Risperidone (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (flexible dosing starting at 0.02 mg/kg/day, titrated up to 0.06 mg/kg/day)
Trial: 10755740
Drug: Morphine 0
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0 mg/70 kg
Trial: 10755740
Drug: Morphine 4
RxNorm normalized name: morphine 4 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 4 mg/70 kg
Trial: 10755740
Drug: Morphine 8
RxNorm normalized name: morphine 8 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 8 mg/70 kg
Trial: 10755740
Drug: Morphine 16
RxNorm normalized name: morphine sulfate 16 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 16 mg/70 kg
Trial: 10755740
Drug: Morphine 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 32 mg/70 kg
Trial: 10755740
Drug: Morphine (lowest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (lowest and highest doses repeated)
Trial: 8677754
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose LPS (1 microgram/ml)
Trial: 8677754
Drug: Lower LPS
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower LPS concentration (1 ng/ml)
Trial: 29336645
Drug: Supervised individually
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised individually tailored exercise program (4-6 weeks), aerobic endurance, muscle strength, and relaxation exercises, administered twice a week
Trial: 23211420
Drug: LCPUFA (n-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPUFA (n-3 long-chain polyunsaturated fatty acids) supplementation at 84 g/day from day 60 of gestation through 21-day lactation and until day 30 of second gestation
Trial: 21769058
Drug: Nicotine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (21 mg transdermal patch)
Trial: 9042638
Drug: Interferon-alpha-2c plus
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2c plus standard induction chemotherapy (three cycles of cyclophosphamide/vincristine/doxorubicin and cisplatin/etoposide plus subcutaneous IFN-alpha-2c)
Trial: 8198267
Drug: Epidural alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Trial: 8198267
Drug: Subcutaneous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Trial: 3440099
Drug: N-desmethylclobazam (NDMC)
RxNorm normalized name: N-ethylurea
DrugBank: Norclobazam (DB17092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-desmethylclobazam (NDMC) 30 mg single dose
Trial: 3440099
Drug: Clobazam 30
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 30 mg single dose
Trial: 27554227
Drug: Dexem group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexem group (15 mL of 0.75% ropivacaine plus dexmedetomidine, 1 µg/kg bolus, followed by 0.2 µg/kg/hour infusion)
Trial: 7498356
Drug: Randomised consent
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised consent (for experimental therapy)
Trial: 7498356
Drug: Randomised consent
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised consent (for standard therapy)
Trial: 2031498
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment in TOHP (Trials of Hypertension Prevention)
Trial: 2031498
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment in HPT (Hypertension Prevention Trial)
Trial: 7214987
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam intravenous supplement
Trial: 7214987
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo (solvent of diazepam only)